carocell biotech

menu.png

Our pipeline products are designed to interrupt the inflammatory cascade and have the potential to provide new therapeutic options to patients with inflammatory diseases

Our research and what we do

Carocell Bio – developing new possibilities for the treatment of inflammatory diseases. 

Carocell Bio has licensed two very important components that have the potential to develop into innovative new treatments for patients with serious inflammatory diseases, including inflammatory bowel disease (IBD), atopic dermatitis and burns.

  • Novel therapeutic peptides: JEL3108, JEL0305, JEL1103, JEL2603 and JEL0802
  • Safe, established nano-polymer delivery technology


Carocell Bio’s peptides

Carocell Bio’s therapeutic peptides are highly potent and selective inhibitors of intracellular p38 mitogen-activated protein (MAP) kinases.

Our Development Pipeline

Carocell Bio is developing a portfolio of combination molecules designed to inhibit the inflammatory cascade

We are combining small molecule p38α inhibitors, initially developed by AstraZeneca, with Nanocin drug reformulation technology to create unique nanoparticles

These combinations have demonstrated significant benefits in cellular studies and warrant further investigation

 

our therapy areas

106 billion dollar market

Our Unique Proposition for the Treatment of Inflammation

MODE OF ACTION

Unique MOA

Peptide + delivery system combination

Blocks p38α activation and reactivation

Reduces pro-inflammatory cytokine production

ADMINISTRATION

Topical, not systemic

Soothing, therapeutic creams for skin conditions

Gel/delayed release oral capsule for IBD

 

ADMINISTRATION

Topical, not systemic

Soothing, therapeutic creams for skin conditions

Gel/delayed release oral capsule for IBD

 

EFFICACY

Potent inflammation inhibitor

Ability to ‘halt’ inflammation at the top of the intracellular inflammation cascade

SAFETY

Simple safety profile

Rapidly broken down into amino acids in serum

No liver toxicity

INDICATIONS

Improved therapeutic option

First-line in patients with mild-to-moderate symptoms

bridge biotec facebookbridge biotec twitterbridge biotec linkedinbridge-youtube-60x60.png

Contact

Email: contact@carocellbio.com
UK: +44 (0) 20 3097 1979
US: +1 212 863 9902

USA Office

Carocell Bio, Inc.
500 Delaware Avenue
Ste#1, 1960
Wilmington
DE 19899
USA

UK Office

Carocell Bio Ltd.
28a London Rd
Alderley Edge
Macclesfield
SK9 7DZ
UK

 

Copyright Carocell Bio Ltd. ©2020